Solvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy Capabilities
Cergentis enables Solvias to provide customers with proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.
News Summary
- Solvias, one of the world’s leading independent pharmaceutical
testing and manufacturing companies, has acquired Netherlands-based Cergentis to
bolster its biologics and cell & gene therapy testing capabilities.
- With global sales of cell & gene therapies projected to accelerate
at a 63% compound annual growth rate, more researchers require sophisticated solutions
to validate the safety & efficacy of these advanced new therapies.
- Cergentis enables Solvias to provide customers with proprietary
technology and knowledge steeped in fast-evolving genomic techniques that support
effective decision-making and R&D program design.
